Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Xenon Pharmaceuticals Inc.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04912856CT.gov An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE | — | Terminated | — | — | — |
NCT04639310CT.gov XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy | — | Terminated | — | — | — |
NCT01777139CT.gov A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures | — | Completed | — | — | — |
NCT01823159CT.gov Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study | — | Completed | — | — | — |
NCT01607346CT.gov An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures | — | Terminated | — | — | — |
NCT01721317CT.gov Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures | — | Terminated | — | — | — |
NCT01668654CT.gov Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS | — | Terminated | — | — | — |
NCT01721213CT.gov Trobalt™ Products Risk Survey | — | Completed | — | — | — |
NCT01648101CT.gov Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures | — | Terminated | — | — | — |
NCT01494584CT.gov Study in Pediatric Subjects With Epilepsy | — | Terminated | — | — | — |
Show 10 more trialsShow fewer
NCT01462669CT.gov Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects | — | Completed | — | — | — |
NCT01583036CT.gov An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed | — | Completed | — | — | — |
NCT01480609CT.gov Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite | — | Completed | — | — | — |
NCT01336621CT.gov Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) | — | Completed | — | — | — |
NCT01587339CT.gov Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy | — | Completed | — | — | — |
NCT01227902CT.gov Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures | — | Completed | — | — | — |
NCT00310388CT.gov Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097 | — | Terminated | — | — | — |
NCT00310375CT.gov Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial | — | Completed | — | — | — |
NCT00235755CT.gov Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy | — | Completed | — | — | — |
NCT00232596CT.gov Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Retigabine (this asset) | Xenon Pharmaceuticals Inc. | Approved | BB · 69 |
| Lamotrigine | Assiut University | P4 | BBB |
| Eslicarbazepine Acetate | Bial - Portela C S.A. | P4 | BBB |
| Topiramate | Université de Sherbrooke | P4 | BBB |
| Levetiracetam | Beijing Tiantan Hospital | P4 | BBB |
| Neurotop | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Lacosamide | Second Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Valproic Acid | Sanofi | P4 | BBB |
| Midazolam | Haseki Training and Research Hospital | P4 | BBB |
+42 more in the Epilepsy cohort
Other indications for Retigabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease | — | P3 | CCC · 54 |
| Childhood-Onset Epilepsy Syndrome | — | P3 | CCC · 54 |
| Central Nervous System Disorder | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Retigabine in Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/retigabine-epilepsy-31499
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →